Detalles de la búsqueda
1.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
J Eur Acad Dermatol Venereol
; 37(5): 894-906, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36433688
2.
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
J Immunother Cancer
; 10(6)2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35688555
3.
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Eur J Cancer
; 166: 60-72, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35279471
4.
Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients.
J Immunother
; 44(6): 239-241, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028389
5.
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.
Cancers (Basel)
; 13(10)2021 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34065995
6.
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
J Immunother Cancer
; 8(2)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33093156
7.
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
J Clin Oncol
; 37(32): 3000-3008, 2019 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31557067
Resultados
1 -
7
de 7
1
Próxima >
>>